Skip to main content
RXRX
NASDAQ Life Sciences

Recursion Beats Q3 Revenue Estimates With $18.1M, Narrows Loss

Tom Rudovsky · Reported by Reuters
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$3.8
Mkt Cap
$2.29B
52W Low
$2.77
52W High
$5.76
52W Position info
37% above low
Off High info
34% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

RXRX sits 37% above its 52-week low of $2.77.

Summary

Recursion posted Q3 operating revenue of $18.055 million against an IBES estimate of $14.8 million, a clear beat. The net loss came in at $119.036 million versus the -$121.7 million consensus, so the loss was slightly smaller than expected. That follows Q2, when revenue of $7.3 million missed consensus by 39% on weaker Roche/Genentech collaboration revenue, so this quarter reverses that trend. The company is still burning heavily, with an operating loss of $123.176 million, and it raised $200 million in an October stock offering at $3.25 a share to fund that burn. The quarter also brought a $10 million Sanofi milestone, positive clinical data in REC-4881 and REC-1245, a Sanofi development candidate option, and the appointment of Fred Hassan as chair, and the company extended its cash runway. The revenue beat and narrower loss support the cost-cut story from Q2, when management lowered expense guidance and extended its cash runway.

At the time of this announcement, RXRX was trading at $3.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.3B. The 52-week trading range was $2.77 to $5.76. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.


Price Chart

Share this article

Copied!

RXRX - Latest Insights

RXRX
Nov 02, 2026, 4:34 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $3.82
Real-time Price: $2.65 info
Change: -$1.17 (-31%) info
Market Cap: $1.696B info
RXRX
Nov 02, 2026, 4:32 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.83
Real-time Price: $2.65 info
Change: -$1.18 (-31%) info
Market Cap: $1.696B info
RXRX
Nov 02, 2026, 4:25 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $3.83
Real-time Price: $2.65 info
Change: -$1.18 (-31%) info
Market Cap: $1.696B info
RXRX
Oct 16, 2026, 3:00 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $4.17
Real-time Price: $2.65 info
Change: -$1.52 (-36%) info
Market Cap: $1.696B info
RXRX
Oct 15, 2026, 8:46 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.72
Real-time Price: $2.65 info
Change: -$1.07 (-29%) info
Market Cap: $1.696B info